Welcome to your daily round-up of everything happening in the world of neurorehab.
Research
Lewy body disease may begin to develop in middle age
Lewy body disease may be more common in middle-aged people than previously thought, according to a recent study. In the study, almost one in ten of over 50-year-olds were found to have tissue markers of Lewy body disease in the brain.
Social, environmental factors raise risk of heart disease and stroke
People who live in areas with social and environmental adversities may have up to twice the increased risk for developing heart disease and stroke, according to new research.
Environmental adversities included air and water pollution, potentially hazardous or toxic sites, few recreational parks and high traffic roads, railways or airports. Social vulnerabilities were defined as racial and ethnic minority status; socioeconomic factors such as income, education and employment levels; housing status; and access to internet and health care.
Risk factors for faster brain ageing revealed
In a new study researchers examined 161 risk factors for dementia, and ranked their impact on this vulnerable brain network, over and above the natural effects of age.
They classified these so-called ‘modifiable’ risk factors – as they can potentially be changed throughout life to reduce the risk of dementia – into 15 broad categories: blood pressure, cholesterol, diabetes, weight, alcohol consumption, smoking, depressive mood, inflammation, pollution, hearing, sleep, socialisation, diet, physical activity, and education.
Company updates
SleepStageML™️gets FDA clearance
Beacon Biosignals has received FDA clearance for SleepStageML™️, an advanced machine learning software that automatically stages sleep from electroencephalogram (EEG) signals of clinical polysomnography (PSG) recordings to aid in the diagnosis and evaluation of sleep and sleep-related disorders. The model was trained on a dataset containing hundreds of thousands of hours of PSG recordings from both healthy individuals and patients with a diverse set of sleep disorders, neurologic disease, and psychiatric disease.
The9 and WM Therapeutic announce share agreement
Internet company, The9, has signed a definitive share purchase agreement with WM Therapeutic , a company operating Generative AI (GenAI) large language model (LLM) multi-dimensional and multi-omics digital precision medicine platform for brain disease.
Avicenna.AI secures FDA clearance for healthcare solutions
Medical imaging AI company Avicenna.AI has received FDA approval for its CINA-iPE and CINA-ASPECTS products. The company’s algorithms enable incidental detection of pulmonary embolism and automatic assessment of stroke severity.
Brain Trust Bio receives approval for ALS trials
Brain Trust Bio (BTB) has received approval to commence Phase I clinical trials in Australia for its Continuous Intrathecal Drug Delivery Method. This milestone paves the way for a pioneering approach in the management of debilitating neurological conditions, including amyotrophic lateral sclerosis (ALS).
